 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Nichi-Iko Pharmaceutical Co., Ltd. is the largest generic drug manufacturer in Japan by sales. In FY2014, it became the first Japanese generic medicine manufacturer to reach JPY100 billion in annual sales, and consolidated net sales in the fiscal year ended March 31, 2016 reached JPY143.5 billion.  Since its establishment in 1965, Nichi-Iko has earned a reputation for operating at the forefront of quality assurance with premium quality generic pharmaceuticals. It has grown market share with an extensive lineup of more than 1,000 commercialized products — the largest number among domestic pharmaceutical manufacturers — as well as strong relationships with wholesalers. Nichi-Iko’s development has been enhanced by six acquisitions and nine business alliances since the appointment of current President & CEO Yuichi Tamura in 2000.  Nichi-Iko employs 1,142 people and operates seven production sites, one R&D facility, and four distribution centers throughout Japan. In Obelisk, its seventh Medium-term Business Plan for the three fiscal years from April 2016 through March 2019, Nichi-Iko aims to become a global Top 10 generics company, underpinned by three core strategies: Power of Expansion, Power of Production, and Power of Development.

52-Wk High	$0.359
52-Wk Low	$0.359

NHKFF Nichi-iko Pharmaceutical Co., Ltd.

About

Feed

News

Earnings

Fundamentals